aica ribonucleotide and Granulocytic Leukemia, Chronic

aica ribonucleotide has been researched along with Granulocytic Leukemia, Chronic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Liang, HT; Liu, W; Tang, L; You, Y; Zhu, XJ; Zhu, XY; Zou, P	1
Altman, JK; Donato, NJ; Glaser, H; Platanias, LC; Vakana, E	1

Other Studies

2 other study(ies) available for aica ribonucleotide and Granulocytic Leukemia, Chronic

Article	Year
AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity. Current medical science, 2020, Volume: 40, Issue:5 Topics: Aminoimidazole Carboxamide; Apoptosis; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Protein Kinase Inhibitors; Ribonucleotides	2020
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood, 2011, Dec-08, Volume: 118, Issue:24 Topics: Amino Acid Substitution; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Line, Transformed; Cell Survival; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metformin; Molecular Targeted Therapy; Mutant Proteins; Prodrugs; Protein Kinases; Recombinant Proteins; Ribonucleotides	2011

Article

Year

AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity.

Current medical science, 2020, Volume: 40, Issue:5

Topics: Aminoimidazole Carboxamide; Apoptosis; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Protein Kinase Inhibitors; Ribonucleotides

2020

Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.

Blood, 2011, Dec-08, Volume: 118, Issue:24

Topics: Amino Acid Substitution; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Line, Transformed; Cell Survival; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metformin; Molecular Targeted Therapy; Mutant Proteins; Prodrugs; Protein Kinases; Recombinant Proteins; Ribonucleotides

2011